Medical comorbidity of binge eating disorder: response
- 208 Downloads
Compliance with ethical standards
Conflict of interest
Drs. Olguin, Fuentes and Gabler have no conflicts of interest to disclose. Dr. McElroy is a consultant to or member of the scientific advisory boards of Bracket, F. Hoffmann-La Roche Ltd., MedAvante, Myriad, Naurex, Novo Nordisk, Shire, and Sunovion. She is a principal or co-investigator on studies sponsored by the Alkermes, Forest, Marriott Foundation, National Institute of Mental Health, Naurex, Orexigen Therapeutics, Inc., Shire, Sunovion, and Takeda Pharmaceutical Company Ltd. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson, which has exclusive rights under the patent. Dr. Keck is employed by the University of Cincinnati College of Medicine and University of Cincinnati Physicians. Dr. Keck is presently or has been in the past year a principal or co-investigator on research studies sponsored by: Cephalon, Marriott Foundation, National Institute of Mental Health (NIMH), Shire. Dr. Keck has been reimbursed for consulting to: 2014: Shire, Supernus, Otsuka, ProPhase, Merck. Dr. Paul E. Keck, Jr. is a co-inventor on United States Patent No. 6,387,956: Shapira NA, Goldsmith TD, Keck, PE Jr. (University of Cincinnati) Methods of treating obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual. Filed March 25, 1999; approved May 14, 2002. Dr. Keck has received no financial gain from this patent. Dr. Guerdjikova is employed by the University of Cincinnati College of Medicine and is a consultant for Bracket.